ARHS · Arhaus, Inc.

Current Thesis

Arhaus's order-recovery thesis requires faster delivered-sales growth at Q3 results and recovery of the lost $9.00 market shelf before a weekly close below $8.00 invalidates it. The 2026-09-11 adjusted close was $8.10, below the $8.98 close recorded on 2026-08-28. The operating premise remains the gap between Q2 2026 comparable written-sales growth of 12.5% and delivered-sales growth of 4.0%, reported on 2026-08-06. Conversion of those orders remains an inference, not a reported result. Arhaus Q2 results.

The narrative is maturing — the order inflection has been public since 2026-08-06, while the supplied adjusted closes show further deterioration through 2026-09-11. The September refresh also changes the insider evidence: a 2026-09-10 filing reports a director sale, superseding the earlier absence-of-selling observation. Neither that transaction nor the price decline establishes weaker customer demand. Director Form 4.

Bullish and bearish views on Arhaus, Inc.

The model's bull view on Arhaus, Inc. (ARHS), in brief: Orders outpaced delivered sales. Arhaus reported Q2 2026 comparable written-sales growth of 12.5% against delivered-sales growth of 4.0% on 2026-08-06. The recovery case requires subsequent conversion; Q3 delivered growth at or below the company's negative 1% guidance floor… The bear view: Tariff recoveries complicate profit comparisons. Both cases follow in full.

Bull Case

• Orders outpaced delivered sales. Arhaus reported Q2 2026 comparable written-sales growth of 12.5% against delivered-sales growth of 4.0% on 2026-08-06. The recovery case requires subsequent conversion; Q3 delivered growth at or below the company's negative 1% guidance floor would contradict it. Q2 results.
• Liquidity accompanies the order recovery. Arhaus reported $226 million in cash and no long-term debt at 2026-06-30. These are balance-sheet facts, not evidence that the market decline has ended. Q2 results.

Bear Case

• Tariff recoveries complicate profit comparisons. Q2 2026 gross profit included a $23.8 million tariff-recovery benefit. The 2026-08-06 release also identified $14.0 million primarily related to inventory-cost reductions at 2026-06-30; Q3 cannot be assumed free of recovery effects. Q2 results.
• Guidance permits weaker delivered demand. On 2026-08-06, management forecast Q3 revenue of $355–375 million and comparable delivered-sales growth of negative 1% to positive 5%. The forecast allows the written-order improvement to coexist with a delivered-sales decline. Q2 results.

Setup & Price Structure

The supplied split- and dividend-adjusted series places the 2026-09-11 close at $8.10, with a three-month price increase of 13.0% and a 14-period relative strength index (RSI) of 26.9. The shares stood 28.4% below the supplied 52-week high of $11.31. These observations document price weakness; they do not establish a reversal. No moving-average value or participation series is available to substantiate a rising-average or expanding-demand claim.

The $9.00 shelf identified in the August coverage remains unrecovered at the 2026-09-11 close. A weekly close above $9.00 would satisfy the price component of the recovery case; a weekly close below $8.00 would end it. The September reference close leaves the case unconfirmed and supports low conviction.

Director Alton F. Doody III reported selling 3,500 Class A shares on 2026-09-08 at $8.47 in his 2026-09-10 Form 4. This is an observable insider transaction, not evidence of issuance or broad insider distribution. The sample is too small to support a crowding claim, and no dated retail-sentiment or short-interest series establishes one. Director Form 4.

Catalyst Calendar (next 30 days)

As of 2026-09-13, the company's event calendar does not list a Q3 2026 earnings date. The previously scheduled 2026-09-09 Barclays appearance is elapsed. No confirmed Q3 reporting date is available for publication. Arhaus events, conference announcement.

Elapsed catalysts

• 2026-09-15 — Piper Sandler Growth Frontiers Conference. Arhaus's 2026-08-12 announcement schedules management investor meetings in Nashville and states that they will not be webcast. The appearance does not itself provide a public operating update; only a subsequent disclosure could resolve the conversion question. Conference announcement. (passed 5d ago)

What Would Change Our Mind

Loss of the remaining $8.00 threshold would break the residual recovery structure: a weekly close below $8.00 invalidates the thesis, retaining the condition published on 2026-08-30. Q3 comparable delivered-sales growth at or below negative 1%, the floor of management's 2026-08-06 guidance, would separately contradict the conversion case.

For the thesis to play out, Q3 comparable delivered-sales growth must exceed Q2 2026's reported 4.0%, and the market must record a weekly close above the lost $9.00 shelf before the $8.00 invalidation fires. These are research conditions, not reported outcomes.

Correlation Notes

This remains a single-company order-conversion case. Arhaus's 2026-08-06 outlook explicitly cited consumer uncertainty and the timing of written-order conversion, supporting those exposures as relevant operating variables. The available evidence contains no matched peer-return or housing-data series; it cannot establish a measured correlation or a category-wide recovery. Q2 outlook.